The Postbiotic Activity of Lactobacillus paracasei 28.4 Against Candida auris
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Candida auris has emerged as a medically important pathogen with considerable resistance to antifungal agents. The ability to produce biofilms is an important pathogenicity feature of this species that aids escape of host immune responses and antimicrobial agents. The objective of this study was to verify antifungal action using in vitro and in vivo models of the Lactobacillus paracasei 28.4 probiotic cells and postbiotic activity of crude extract (LPCE) and fraction 1 (LPF1), derived from L. paracasei 28.4 supernatant. Both live cells and cells free supernatant of L. paracasei 28.4 inhibited C. auris suggesting probiotic and postbiotic effects. The minimum inhibitory concentration (MIC) for LPCE was 15 mg/mL and ranges from 3.75 to 7.5 mg/mL for LPF1. Killing kinetics determined that after 24 h treatment with LPCE or LPF1 there was a complete reduction of viable C. auris cells compared to fluconazole, which decreased the initial inoculum by 1-logCFU during the same time period. LPCE and LPF1 significantly reduced the biomass (p=0.0001) and the metabolic activity (p=0.0001) of C. auris biofilm. There was also a total reduction (~108 CFU/mL) in viability of persister C. auris cells after treatment with postbiotic elements (p<0.0001). In an in vivo study, injection of LPCE and LPF1 into G. mellonella larvae infected with C. auris prolonged survival of these insects compared to a control group (p<0.05) and elicited immune responses by increasing the number of circulating hemocytes and gene expression of antimicrobial peptide galiomicin. We concluded that the L. paracasei 28.4 cells and postbiotic elements (LPCE and LPF1) have antifungal activity against planktonic cells, biofilms, and persister cells of C. auris. Postbiotic supplementation derived from L. paracasei 28.4 protected G. mellonella infected with C. auris and enhanced its immune status indicating a dual function in modulating a host immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 3×
“The emergence of C. auris is concerning because this yeast has or may develop resistance to different antifungal agents (Lockhart et al., 2017; Chaabane et al., 2019), making infections difficult to treat.”
BackgroundCandida albicans Biofilms Produce Antifungal-Tolerant Persister Cells
LaFleur, M. D., Kumamoto, C. A., & Lewis, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00684-06 · Cited by 521
Pathogenic relevance of Lactobacillus: A retrospective review of over 200 cases
Cannon, J. P., Lee, T. A., Bolanos, J. T., & Danziger, L. H. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1253-y · Cited by 478 · cited 9×
“, 2018), but their clinical application in immunocompromised patients is limited due to the possibility of bacteremia caused by bacteria of the genus Lactobacillus (Cannon et al., 2005; Salminen et al., 2006).”
BackgroundInfluentialBiofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris
Sherry, L., Ramage, G., Kean, R., Borman, A., Johnson, E. M., Richardson, M. D., & Rautemaa-Richardson, R. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161320 · Cited by 420
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics October 2011
Guarner, F., Khan, A. G., Garisch, J., Eliakim, R., Gangl, A., Thomson, A., Krabshuis, J., Lemair, T., Kaufmann, P., de Paula, J. A., et al. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182549092 · Cited by 418
Candida auris: an Emerging Fungal Pathogen
Spivak, E. S., & Hanson, K. E. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01588-17 · Cited by 393
Candida albicans dimorphism as a therapeutic target
Jacobsen, I. D., Wilson, D., Wächtler, B., Brunke, S., Naglik, J. R., & Hube, B. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.152 · Cited by 363 · cited 1×
“This genus are responsible the main opportunistic yeast infection in the world (Jacobsen et al., 2012; Wachtler et al., 2012; Martins et al., 2014).”
BackgroundPfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352 · cited 1×
“If the MFC is ≤4×MIC the drug is considered cidal (Pfaller et al., 2004).”
BackgroundBorman, A. M., Szekely, A., & Johnson, E. M. (2016) · mSphere · doi:10.1128/msphere.00189-16 · Cited by 333
Wächtler, B., Citiulo, F., Jablonowski, N., Förster, S., Dalle, F., Schaller, M., Wilson, D., & Hube, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036952 · Cited by 250 · cited 1×
“This genus are responsible the main opportunistic yeast infection in the world (Jacobsen et al., 2012; Wachtler et al., 2012; Martins et al., 2014).”
BackgroundReview on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris
Chaabane, F., Graf, A., Jequier, L., & Coste, A. T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02788 · Cited by 223
Kean, R., Delaney, C., Sherry, L., Borman, A., Johnson, E. M., Richardson, M. D., Rautemaa-Richardson, R., Williams, C., & Ramage, G. (2018) · mSphere · doi:10.1128/msphere.00334-18 · Cited by 220
Salminen, M. K., Rautelin, H., Tynkkynen, S., Poussa, T., Saxelin, M., Valtonen, V., & Jarvinen, A. (2006) · Clinical Infectious Diseases · doi:10.1086/500214 · Cited by 218
Matsubara, V. H., Wang, Y., Bandara, H. M. H. N., Mayer, M. P. A., & Samaranayake, L. P. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7527-3 · Cited by 206
Probiotics as antifungals in mucosal candidiasis
Matsubara, V. H., Bandara, H. M. H. N., Mayer, M. P. A., & Samaranayake, L. P. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw038 · Cited by 151 · cited 1×
“In this context, the use of probiotics has been considered a promising strategy for prevention and control of several fungal infections (Mailander-Sanchez et al., 2012; Matsubara et al., 2016a; Hu et al., 2017; Rodrigues C. F. et al., 2019).”
BackgroundSabino, R., Veríssimo, C., Pereira, Á. A., & Antunes, F. (2020) · Microorganisms · doi:10.3390/microorganisms8020181 · Cited by 133
Absence of Amphotericin B-Tolerant Persister Cells in Biofilms of Some Candida Species
Al-Dhaheri, R. S., & Douglas, L. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01473-07 · Cited by 99 · cited 2×
“In addition, Al-Dhaheri and Douglas (2008) showed that not all Candida spp. and strains are able to form persister cells, Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9 August 2020 | Volume 10 | Article 397 for example, C. albicans strain SC5314 (Gillum et al., 1984), one…”
BackgroundMethodCandida auris: An emerging pathogen “incognito”?
Nett, J. E. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1007638 · Cited by 69
Candida albicans Biofilms Are Generally Devoid of Persister Cells
Denega, I., d’Enfert, C., & Bachellier-Bassi, S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01979-18 · Cited by 32
Research works printed but not linked: 54
- Bergin, 2003, Fluctuations in haemocyte density and microbial load may be used as indicators of fungal pathogenicity in larvae of Galleria mellonella, Microbes Infect, 5, 1389, 10.1016/j.micinf.2003.09.019 · DOI
- Bidaud, 2018, Candida auris: an emerging drug resistant yeast—a mini-review, J. Mycol. Med, 28, 568, 10.1016/j.mycmed.2018.06.007 · DOI · Paper page
- Bigger, 1944, Treatment of Staphylococcal infections with penicillin by intermittent sterilisation, Lancet, 244, 497, 10.1016/S0140-6736(00)74210-3 · DOI · Paper page
- 2016, Global Emergence of Invasive Infections Caused by the Multidrug-Resistant Yeast Candida auris
- Cernakova, 2019, Novel therapies for biofilm-based Candida spp. infections, Adv. Exp. Med. Biol, 1214, 93, 10.1007/5584_2019_400 · DOI
- Chakrabarti, 2020, Multidrug-resistant Candida auris: an epidemiological review, Expert Rev. Anti Infect. Ther, 18, 551, 10.1080/14787210.2020.1750368 · DOI · Paper page
- Cicenia, 2014, Postbiotic activities of lactobacilli-derived factors, J. Clin. Gastroenterol, 48, S18, 10.1097/MCG.0000000000000231 · DOI · Paper page
- Compare, 2017, Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome, BMC Gastroenterol, 17, 53, 10.1186/s12876-017-0605-x · DOI · Paper page
- Davies, 2003, Understanding biofilm resistance to antibacterial agents, Nat. Rev. Drug Discov, 2, 114, 10.1038/nrd1008 · DOI · Paper page
- de Barros, 2018, Lactobacillus paracasei 28.4 reduces in vitro hyphae formation of Candida albicans and prevents the filamentation in an experimental model of Caenorhabditis elegans, Microb. Pathog, 117, 80, 10.1016/j.micpath.2018.02.019 · DOI
- Dunand, 2019, Postbiotics produced at laboratory and industrial level as potential functional food ingredients with the capacity to protect mice against Salmonella infection, J. Appl. Microbiol, 127, 219, 10.1111/jam.14276 · DOI
- Gao, 2019, A novel postbiotic from Lactobacillus rhamnosus GG with a beneficial effect on intestinal barrier function, Front. Microbiol, 10, 477, 10.3389/fmicb.2019.00477 · DOI · Paper page
- Geraldo, 2019, Heat-killed Lactobacillus reuteri and cell-free culture supernatant have similar effects to viable probiotics during interaction with Porphyromonas gingivalis, J. Periodontal. Res., 55, 215, 10.1111/jre.12704 · DOI · Paper page
- Gillum, 1984, Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations, Mol. Gen. Genet, 198, 179, 10.1007/BF00328721 · DOI · Paper page
- Hu, 2017, Probiotics prevent Candida colonization and invasive fungal sepsis in preterm neonates: a systematic review and meta-analysis of randomized controlled trials, Pediatr. Neonatol, 58, 103, 10.1016/j.pedneo.2016.06.001 · DOI · Paper page
- Janczarek, 2016, The role of probiotics in prevention of oral diseases, Postepy Hig. Med. Dosw., 70, 850, 10.5604/17322693.1214381 · DOI
- Jin, 2004, Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars, Arch. Oral Biol, 49, 789, 10.1016/j.archoralbio.2004.04.011 · DOI · Paper page
- Johnson, 2019, Administration of a postbiotic causes immunomodulatory responses in broiler gut and reduces disease pathogenesis following challenge, Microorganisms, 7, 268, 10.3390/microorganisms7080268 · DOI · Paper page
- Kavanagh, 2004, Exploiting the potential of insects for in vivo pathogenicity testing of microbial pathogens, FEMS Microbiol. Rev, 28, 101, 10.1016/j.femsre.2003.09.002 · DOI · Paper page
- Mailander-Sanchez, 2012, Potential role of probiotic bacteria in the treatment and prevention of localised candidosis, Mycoses, 55, 17, 10.1111/j.1439-0507.2010.01967.x · DOI
- Martins, 2014, Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment, Mycopathologia, 177, 223, 10.1007/s11046-014-9749-1 · DOI · Paper page
- Medina, 2019, Botryane terpenoids produced by Nemania bipapillata, an endophytic fungus isolated from red alga Asparagopsis taxiformis—Falkenbergia stage, Sci. Rep, 9, 12318, 10.1038/s41598-019-48655-7 · DOI
- Mosca, 2019, Can postbiotics represent a new strategy for NEC?, Adv. Exp. Med. Biol, 1125, 37, 10.1007/5584_2018_314 · DOI
- Mowlds, 2010, Dose-dependent cellular and humoral responses in Galleria mellonella larvae following beta-glucan inoculation, Microbes Infect, 12, 146, 10.1016/j.micinf.2009.11.004 · DOI
- Mylonakis, 2005, Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis, Infect. Immun, 73, 3842, 10.1128/IAI.73.7.3842-3850.2005 · DOI · Paper page
- 2002, “Reference method for broth dilution antifungal susceptibility testing of yeasts,”
- Pathirana, 2018, Fluconazole-resistant Candida auris is susceptible to salivary histatin 5 killing and to intrinsic host defenses, Antimicrob. Agents Chemother, 62, e01872, 10.1128/AAC.01872-17 · DOI · Paper page
- Peeters, 2008, Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates, J. Microbiol. Methods, 72, 157, 10.1016/j.mimet.2007.11.010 · DOI · Paper page
- Peleg, 2008, Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans, Proc. Natl. Acad. Sci. U. S. A., 105, 14585, 10.1073/pnas.0805048105 · DOI · Paper page
- Pereira, 2018, Recent advances in the use of galleria mellonella model to study immune responses against human pathogens, J. Fungi., 4, 128, 10.3390/jof4040128 · DOI · Paper page
- Ribeiro, 2017, Lactobacillus rhamnosus inhibits Candida albicans virulence factors in vitro and modulates immune system in Galleria mellonella, J. Appl. Microbiol, 122, 201, 10.1111/jam.13324 · DOI · Paper page
- Ribeiro, 2020, Development of probiotic formulations for oral candidiasis prevention: Gellan gum as a carrier to deliver Lactobacillus paracasei 28.4, Antimicrob. Agents Chemother, 6, e02323, 10.1128/AAC.02323-19 · DOI
- Riccardi, 2019, Definition of opportunistic infections in immunocompromised children on the basis of etiologies and clinical features: a summary for practical purposes, Curr. Pediatr. Rev, 15, 197, 10.2174/1573396315666190617151745 · DOI
- Rodrigues, 2019, Promising alternative therapeutics for oral candidiasis, Curr. Med. Chem, 26, 2515, 10.2174/0929867325666180601102333 · DOI
- Rodrigues, 2019, Candida spp./bacteria mixed biofilms, J. Fungi., 6, 5, 10.3390/jof6010005 · DOI · Paper page
- Rodrigues, 2016, Novel strategies to fight Candida species infection, Crit. Rev. Microbiol, 42, 594, 10.3109/1040841X.2014.974500 · DOI
- Rossato, 2018, Candida auris: what have we learned about its mechanisms of pathogenicity?, Front. Microbiol, 9, 3081, 10.3389/fmicb.2018.03081 · DOI · Paper page
- Rossoni, 2018, Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis, Biofouling, 34, 212, 10.1080/08927014.2018.1425402 · DOI · Paper page
- Rossoni, 2019, C. albicans infection. Biofouling, 35, 997, 10.1080/08927014.2019.1686485 · DOI
- Rossoni, 2017, Lactobacillus paracasei modulates the immune system of Galleria mellonella and protects against Candida albicans infection, PLoS ONE, 12, e0173332, 10.1371/journal.pone.0173332 · DOI
- Santos, 2019, Lactobacillus species increase the survival of Galleria mellonella infected with Candida albicans and non-albicans Candida clinical isolates, Med. Mycol, 57, 391, 10.1093/mmy/myy032 · DOI
- Scalfaro, 2017, Galleria mellonella as an in vivo model for assessing the protective activity of probiotics against gastrointestinal bacterial pathogens, FEMS Microbiol. Lett, 364, 1, 10.1093/femsle/fnx064 · DOI
- Sekyere, 2018, Emerging mechanisms of antimicrobial resistance in bacteria and fungi: advances in the era of genomics, Future Microbiol, 13, 241, 10.2217/fmb-2017-0172 · DOI
- Serra, 2015, Vertical stratification of matrix production is essential for physical integrity and architecture of macrocolony biofilms of Escherichia coli, Environ. Microbiol, 17, 5073, 10.1111/1462-2920.12991 · DOI
- Shai, 2002, Mode of action of membrane active antimicrobial peptides, Biopolymers, 66, 236, 10.1002/bip.10260 · DOI · Paper page
- Sheehan, 2018, Analysis of the early cellular and humoral responses of Galleria mellonella larvae to infection by Candida albicans, Virulence, 9, 163, 10.1080/21505594.2017.1370174 · DOI
- Tharmalingam, 2019, The anti-virulence efficacy of 4-(1,3-dimethyl-2,3-dihydro-1h-benzimidazol-2-yl)phenol against methicillin-resistant Staphylococcus aureus, Front. Microbiol, 10, 1557, 10.3389/fmicb.2019.01557 · doi:10.3389/fmicb.2019.01557
- Tsai, 2016, Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing, Virulence, 7, 214, 10.1080/21505594.2015.1135289 · DOI · Paper page
- Tsilingiri, 2012, Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model, Gut, 61, 1007, 10.1136/gutjnl-2011-300971 · DOI · Paper page
- Tsilingiri, 2013, Postbiotics: what else?, Benef. Microbes, 4, 101, 10.3920/BM2012.0046 · DOI · Paper page
- Vicariotto, 2012, Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study, J. Clin. Gastroenterol, 46, S73, 10.1097/MCG.0b013e3182684d71 · DOI · Paper page
- Vilela, 2015, Lactobacillus acidophilus ATCC 4356 inhibits biofilm formation by C. albicans and attenuates the experimental candidiasis in Galleria mellonella, Virulence, 6, 29, 10.4161/21505594.2014.981486 · DOI · Paper page
- Wegh, 2019, Postbiotics and their potential applications in early life nutrition and beyond, Int. J. Mol. Sci, 20, 4673, 10.3390/ijms20194673 · DOI · Paper page
- Wojda, 2017, Immunity of the greater wax moth Galleria mellonella, Insect. Sci, 24, 342, 10.1111/1744-7917.12325 · doi:10.1111/1744-7917.12325
Cited by
Postbiotics: Current Trends in Food and Pharmaceutical Industry
Thorakkattu, P., Khanashyam, A. C., Shah, K., Babu, K. S., Mundanat, A. S., Deliephan, A., Deokar, G. S., Santivarangkna, C., & Nirmal, N. P. (2022) · Foods · doi:10.3390/foods11193094 · Cited by 380
Fungal biofilms in human health and disease
Ramage, G., Kean, R., Rautemaa-Richardson, R., Williams, C., & Lopez-Ribot, J. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01147-0 · Cited by 72
Tong, Y., Guo, H., Abbas, Z., Zhang, J., Wang, J., Cheng, Q., Peng, S., Yang, T., Bai, T., Zhou, Y., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1229952 · Cited by 70
Garcia-Bustos, V., Pemán, J., Ruiz-Gaitán, A., Cabañero-Navalon, M. D., Cabanilles-Boronat, A., Fernández-Calduch, M., Marcilla-Barreda, L., Sigona-Giangreco, I. A., Salavert, M., Tormo-Mas, M. Á., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2017756 · Cited by 30
“albicans as previously reported in a qualitative manner [34].”
BackgroundKaynakci, E. C. (2025) · Scientific Reports · doi:10.1038/s41598-025-09913-z · Cited by 16
Metadata
- Authors
- Rossoni, R. D., de Barros, P. P., Mendonça, I. D. C., Medina, R. P., Silva, D. H. S., Fuchs, B. B., Junqueira, J. C., & Mylonakis, E.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-04
- Volume
- 10
- Pages
- 397-397
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W3041615144
- Cited by
- 102
- References
- 19
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2017/19219-3, 2018/21239-5)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (306330/2018-0)
- National Institutes of Health (P20 GM121344)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.